HK1029922A1 - Angiostatic agents and compositions for treating glc1a glaucoma - Google Patents

Angiostatic agents and compositions for treating glc1a glaucoma

Info

Publication number
HK1029922A1
HK1029922A1 HK01100647A HK01100647A HK1029922A1 HK 1029922 A1 HK1029922 A1 HK 1029922A1 HK 01100647 A HK01100647 A HK 01100647A HK 01100647 A HK01100647 A HK 01100647A HK 1029922 A1 HK1029922 A1 HK 1029922A1
Authority
HK
Hong Kong
Prior art keywords
compositions
angiostatic agents
treating
glc1a glaucoma
glaucoma
Prior art date
Application number
HK01100647A
Other languages
English (en)
Inventor
Abbot F Clark
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of HK1029922A1 publication Critical patent/HK1029922A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J11/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027Azides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01100647A 1997-12-19 2001-01-29 Angiostatic agents and compositions for treating glc1a glaucoma HK1029922A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/994,114 US5990099A (en) 1988-10-31 1997-12-19 Angiostatic agents and methods and compositions for controlling ocular hypertension
PCT/US1998/025913 WO1999032127A1 (en) 1997-12-19 1998-12-07 Angiostatic agents and compositions for controlling ocular hypertension

Publications (1)

Publication Number Publication Date
HK1029922A1 true HK1029922A1 (en) 2001-04-20

Family

ID=25540297

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100647A HK1029922A1 (en) 1997-12-19 2001-01-29 Angiostatic agents and compositions for treating glc1a glaucoma

Country Status (13)

Country Link
US (1) US5990099A (es)
EP (1) EP1039912B1 (es)
JP (1) JP2001526233A (es)
AT (1) ATE221781T1 (es)
AU (1) AU734436B2 (es)
BR (1) BR9813684A (es)
CA (1) CA2315829C (es)
DE (1) DE69807115T2 (es)
DK (1) DK1039912T3 (es)
ES (1) ES2177112T3 (es)
HK (1) HK1029922A1 (es)
PT (1) PT1039912E (es)
WO (1) WO1999032127A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1935501A (en) * 1999-12-09 2001-06-18 Alcon Universal Limited Id protein inhibitors for treating ocular diseases
US9820883B2 (en) 2000-05-19 2017-11-21 Michael S. Berlin Method for treating glaucoma
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
WO2003029268A1 (en) * 2001-10-03 2003-04-10 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
WO2007009087A2 (en) * 2005-07-12 2007-01-18 Dmi Biosciences, Inc. Methods and products for treatment of diseases
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
JP2011513002A (ja) 2008-03-05 2011-04-28 イバンティス インコーポレイテッド 緑内障を治療する方法及び器具
DK2278978T3 (en) 2008-05-28 2015-09-21 Reveragen Biopharma Inc NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE
PT2554174E (pt) 2009-06-22 2015-12-15 Ampio Pharmaceuticals Inc Método para o tratamento de doenças
BRPI1010086A2 (pt) * 2009-06-22 2018-02-06 Dmi Acquisition Corp método e produtos para tratamento de doenças
WO2011006078A1 (en) 2009-07-09 2011-01-13 Ivantis, Inc. Single operator device for delivering an ocular implant
AU2010271218B2 (en) 2009-07-09 2017-02-02 Alcon Inc. Ocular implants and methods for delivering ocular implants into the eye
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN108135470B (zh) 2015-08-14 2021-03-09 伊万提斯公司 具有压力传感器和输送系统的眼部植入物
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
EP4274529A1 (en) 2021-01-11 2023-11-15 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642355A (en) * 1984-02-24 1987-02-10 Otsuka Pharmaceutical Factory, Inc. Proline derivatives
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
ATE190623T1 (de) * 1990-06-11 2000-04-15 Alcon Lab Inc Verwendung von steroiden zur inhibierung von angiogenesis
EP0614463B1 (en) * 1991-11-22 2003-02-12 Alcon Laboratories, Inc. Angiostatic steroids
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma

Also Published As

Publication number Publication date
US5990099A (en) 1999-11-23
ES2177112T3 (es) 2002-12-01
ATE221781T1 (de) 2002-08-15
EP1039912B1 (en) 2002-08-07
DK1039912T3 (da) 2002-10-28
EP1039912A1 (en) 2000-10-04
AU734436B2 (en) 2001-06-14
JP2001526233A (ja) 2001-12-18
DE69807115D1 (de) 2002-09-12
AU1714299A (en) 1999-07-12
WO1999032127A1 (en) 1999-07-01
DE69807115T2 (de) 2002-12-12
PT1039912E (pt) 2002-12-31
BR9813684A (pt) 2000-10-10
CA2315829A1 (en) 1999-07-01
CA2315829C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
DE69717312D1 (de) Intestinale absorption von nikotin für die behandlung von nikotinabhängigen zustanden
CY2473B1 (en) New phenanthridines.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
MY114014A (en) Imidazole compounds, compositions and use
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
IL164568A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
PL314799A1 (en) Application of dimeticone in treating constipations
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
HK1039568A1 (en) Use of ap-1 activators to treat glaucoma and ocular hypertension.
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.
AU7799898A (en) Compositions and methods for treating glaucoma
AU3643295A (en) Compositions of melatonin and analgetic agents and methods of use thereof
MX9709450A (es) Piridiniminil-1,2-benzoisoxazoles y -benzoisotiazoles como agentes antipsicoticos.
MX9709912A (es) Compuestos de imidazol, procedimiento para prepararlos y uso de los mismos.
UA31995A (uk) Засіб для профілактики і лікування гіпогалактії
MX9709908A (es) Compuestos cetoheterociclicos, uso de los mismos y composiciones que los contienen.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111207